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Background
A large number of anti-HIV-1 antibodies targeting the
CD4 binding site (CD4bs) on gp120 have recently been
reported. These antibodies, typified by VRC01, are
remarkable for both their breadth and potency. Crystal
structures have revealed a common mode of binding for
several of these antibodies; however, the precise rela-
tionship among CD4bs antibodies remains to be defined.
Methods
We analyze existing structural and sequence data, pro-
pose a set of signature features for potent VRC01-like
(PVL) antibodies, and test the importance of these fea-
tures by mutagenesis.
Results
A group of highly potent CD4bs antibodies, previously
isolated from 5 different individuals, all derive from the
human VH1-2 gene segment and share a set of charac-
teristic residues, including W50, N58, R71, and W100B.
Mutagenesis studies on a half-germline version of a
VRC01-like antibody confirm that these signature resi-
dues are critical for gp120 binding. Neutralization assays
with viruses mutated at sites that contact these critical
antibody residues also confirm the significance of these
interactions.
Conclusion
The signature features explain why PVL antibodies derive
from a single germ-line human VH gene segment and
why certain gp120 sequences are associated with anti-
body resistance. This analysis also suggests that
immunization experiments to elicit VRC01-like antibo-
dies may be problematic in mice or rabbits since they
lack germ-line VH genes with all the critical residues.
Our results bear on vaccine development and structure-
based design to improve the potency and breadth of anti-
CD4bs antibodies.
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